This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HOLX or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
HOLX vs. SONVY: Which Stock Is the Better Value Option?
by Zacks Equity Research
HOLX vs. SONVY: Which Stock Is the Better Value Option?
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Hologic (HOLX) Introduces Genius Digital Diagnostics System
by Zacks Equity Research
Hologic's (HOLX) Genius Digital Diagnostics System will assist laboratories and healthcare providers with the information needed to make more timely and successful treatment decisions for patients.
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic's (HOLX) Q1 Earnings Beat Estimates, Gross Margin Down
by Zacks Equity Research
Hologic's (HOLX) Breast Health segment registered strong growth in Q1, primarily owing to higher capital equipment revenues.
Hologic (HOLX) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Hologic (HOLX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Here's Why You Should Retain Hologic (HOLX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Hologic (HOLX) owing to its strength in the Breast Health and GYN Surgical segments.
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal first-quarter sales.
What Analyst Projections for Key Metrics Reveal About Hologic (HOLX) Q1 Earnings
by Zacks Equity Research
Evaluate the expected performance of Hologic (HOLX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Hologic (HOLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Much a $1000 Investment in Hologic Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
HOLX or SONVY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. SONVY: Which Stock Is the Better Value Option?
3 Medical Instruments Stocks to Buy as Industry Trends Improve
by Urmimala Biswas
The Zacks Medical - Instruments industry is gaining from the rising demand for digital health offers. However, inflation and staffing shortages continue to disrupt growth. HOLX, MASI and VCYT appear well-poised to brave the challenges.
Hologic (HOLX) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Hologic (HOLX) closed at $74.04, indicating a +0.71% shift from the previous trading day.
3 Discounted MedTech Stocks Poised for Sturdy Growth in 2024
by Riya Anand
Prestige Consumer Health (PBH), Quest Diagnostics (DGX) and Hologic (HOLX) are currently at discounted zone that are expected to provide long-term gains.
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
by Zacks Equity Research
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic (HOLX) Q1 Earnings Might Rise on Breast Health Growth
by Zacks Equity Research
Strong performance in the Breast Health segment is likely to boost Hologic's (HOLX) Q1 result.
Why Hologic (HOLX) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Hologic (HOLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Breast Health and GYN Surgical businesses are likely to contribute to Hologic's (HOLX) Q1 2024 revenues.
Hologic (HOLX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the most recent trading session, Hologic (HOLX) closed at $72.89, indicating a +0.19% shift from the previous trading day.
Strength Seen in Intuitive Surgical, Inc. (ISRG): Can Its 10.3% Jump Turn into More Strength?
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Hologic (HOLX) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Hologic (HOLX) closed at $72.12 in the latest trading session, marking a +1.11% move from the prior day.